| COMPANY |
Talis Biomedical Corporation |
| COURT |
United States District Court for the Northern District of California |
| CASE NUMBER |
22-cv-00105 |
| JUDGE |
The Honorable Susan Yvonne Illston |
| CLASS PERIOD |
Talis' February 2021 initial public offering ("IPO") |
| SECURITY TYPE |
Common Stock |
Case Background:
A class action lawsuit has been filed on behalf of those who purchased or acquired Talis Biomedical Corporation (“Talis”) (NASDAQ: TLIS) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Talis’ February 2021 initial public offering (“IPO” or the “Offering”).
The complaint alleges that the Registration Statement failed to disclose to investors that: (1) the comparator assay in the primary study lacked sufficient sensitivity to support Talis’ EUA application for Talis One COVID-19 test; (2) as a result, Talis was reasonably likely to experience delays in obtaining regulatory approval for the Talis One COVID-19 test; (3) as a result, Talis’ commercialization timeline would be significantly delayed; and (4) as a result of the foregoing, the defendants’ positive statements about Talis’ business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Current Status of Case:
On November 22, 2024, The Court entered an Order granting the Lead Plaintiffs Motion for Preliminary Approval of Settlement and scheduled a Final Settlement Hearing on March 14, 2025. This action is ongoing.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453 or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.